<DOC>
	<DOCNO>NCT01788046</DOCNO>
	<brief_summary>This study design assess efficacy safety etelcalcetide ( AMG 416 ) compare placebo treatment SHPT CKD patient receive hemodialysis .</brief_summary>
	<brief_title>Efficacy Safety Etelcalcetide ( AMG 416 ) Treatment Secondary Hyperparathyroidism ( SHPT ) Patients With Chronic Kidney Disease ( CKD ) Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subject understands study procedure agree participate study give write informed consent . Subject 18 year age old . Subject agree participate another study investigational agent study . Subject must receive hemodialysis 3 time weekly least 3 month Other Inclusion Criteria may apply Currently receive treatment another investigational device drug study , end treatment another investigational device drug study ( ) within 8 week prior screen . Other investigational procedure participate study exclude . Anticipated schedule parathyroidectomy study period . Subject receive parathyroidectomy within 3 month prior dose . Anticipated schedule kidney transplant study period . Subject know sensitivity product component administer dose . Subject participate prior clinical trial AMG 416 Subject unstable medical condition base medical history , physical examination , routine laboratory test , otherwise unstable judgment Investigator . Subject history illness , opinion Investigator , might confound result study pose additional risk subject . Other Exclusion Criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Secondary Hyperparathyroidism ( SHPT ) , chronic kidney disease ( CKD ) , hemodialysis , parathyroid hormone ( PTH ) , hypocalcemia , bone mineral metabolism</keyword>
</DOC>